SureTrader Nadex Advertisement
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

IDRA RSS Feed
Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 2/24/2017 11:48:37 AM - Followers: 154 - Board type: Free - Posts Today: 0



The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.


In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.


IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.


The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.

http://www.iderapharma.com/

 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA
Current Price
Volume:
Bid Ask Day's Range
SureTrader
IDRA News: Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combina... 02/24/2017 11:30:00 AM
IDRA News: Statement of Changes in Beneficial Ownership (4) 02/08/2017 04:46:23 PM
IDRA News: Initial Statement of Beneficial Ownership (3) 02/08/2017 04:45:31 PM
IDRA News: Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development 02/06/2017 08:00:00 AM
IDRA News: Current Report Filing (8-k) 01/09/2017 08:01:45 AM
News News Alert: Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combina... 02/24/2017 11:30:00 AM
PostSubject
#2828   From the PR: chmcnfunds 02/24/17 11:48:36 AM
#2827   Idera Pharmaceuticals Presents Update from Ongoing Phase 1 chmcnfunds 02/24/17 11:42:56 AM
#2826   Definitely counter IBB trend. :-) Citrati 02/23/17 06:09:13 PM
#2825   Real strong finish at close with ~50,000 shares chmcnfunds 02/23/17 04:04:45 PM
#2824   I had to add the 200 to my chmcnfunds 02/22/17 08:30:24 AM
#2823   The abstract: chmcnfunds 02/22/17 08:02:30 AM
#2822   As I interpret the ink blot, it entered Citrati 02/21/17 04:17:03 PM
#2821   I imagine we should get a pr tomorrow kld2 02/21/17 11:37:55 AM
#2820   I'm referring to over-bought as evidenced by technical chmcnfunds 02/21/17 10:43:53 AM
#2819   Overbought? I would say it's been oversold for months. kld2 02/21/17 10:02:29 AM
#2818   I agree with you generally except the charts chmcnfunds 02/21/17 09:55:29 AM
#2817   I don't expect much from IDRA abstract. A kld2 02/21/17 06:15:35 AM
#2816   Very much so, 2017-2018 will be a complete Farmmarket1 02/20/17 02:30:38 PM
#2815   Agreed. Excellent addition from you. Citrati 02/20/17 12:57:25 PM
#2814   8:45 into webcast still gets me more excited Farmmarket1 02/20/17 11:30:49 AM
#2813   Check this out if you haven't already. Citrati 02/18/17 10:32:47 PM
#2812   Abstracts: Embargo Policy chmcnfunds 02/17/17 02:00:37 PM
#2811   Solid volume: chmcnfunds 02/17/17 12:17:17 PM
#2810   IDRA, IMO, has the key elements to very kld2 02/17/17 08:33:43 AM
#2809   I think we are seeing some run-up now, Citrati 02/17/17 08:20:56 AM
#2808   citrati, how do you see IDRA playing out kld2 02/17/17 07:21:49 AM
#2807   Thanks for all the posts everyone. Much appreciated. Citrati 02/16/17 10:21:40 PM
#2806   Good information, thanks. I'm guessing they are available chmcnfunds 02/16/17 04:13:15 PM
#2805   Feb 21st is release of abstract on SITC-ASCO jaybe 02/15/17 12:55:55 PM
#2804   IMO, IDRA rebounding from 1.30s has solely been Farmmarket1 02/15/17 12:53:46 PM
#2803   Will do man.. Farmmarket1 02/15/17 12:53:07 PM
#2802   I also sent Bob an email. Please get kld2 02/15/17 12:52:48 PM
#2801   Will say, management has been waiting till a Farmmarket1 02/15/17 12:46:26 PM
#2800   Oh man, actually I couldn't find anything on Farmmarket1 02/15/17 12:44:07 PM
#2799   Farmer, can't seem to find anything on the kld2 02/15/17 12:37:45 PM
#2798   Tremendous quarter in terms of institutional buys. Now 33% chmcnfunds 02/15/17 10:06:23 AM
#2797   Baker Bros still on board. Percentage-wise one of chmcnfunds 02/15/17 08:11:29 AM
#2796   Me too. It's like dots you can't see kld2 02/15/17 06:31:16 AM
#2795   I'm opening a position today after months away kld2 02/15/17 06:28:58 AM
#2794   I believe tomorrow is the last date for chmcnfunds 02/13/17 09:03:41 AM
#2793   Underappreciated no doubt! Go $IDRA Cbdpotential 02/09/17 11:34:43 AM
#2792   Note Tweeted a few minutes ago by $heff chmcnfunds 02/09/17 10:09:25 AM
#2791   Have a pretty good GUT FEELING about this Cbdpotential 02/09/17 12:01:34 AM
#2790   Here's another view. Citrati 02/08/17 09:33:58 PM
#2789   ASCO Feb 23-25th. 8MG dose seems to be Farmmarket1 02/07/17 10:30:54 PM
#2788   I follow too many to keep accurate track, Citrati 02/06/17 03:09:11 PM
#2787   Sure has. Eyeing the $1.59 pivot you have chmcnfunds 02/06/17 03:03:18 PM
#2786   This has improved as well. Citrati 02/06/17 01:00:52 PM
#2785   Impressive background, and apparently approved by the two chmcnfunds 02/06/17 11:01:32 AM
#2784   Bottom feeders may want to sit up and Citrati 02/01/17 09:23:23 PM
#2783   Thanks, 'chmcnfunds'. Citrati 02/01/17 09:21:42 PM
#2782   Reason for the insane volume and rise after-hours yesterday: chmcnfunds 02/01/17 07:58:18 AM
#2781   http://seekingalpha.com/article/4040530-doubling-idera?auth_param=5n2tb:1c8tr5a: Citrati 01/30/17 09:12:44 AM
#2780   Maybe a $heff bump? chmcnfunds 01/24/17 03:45:53 PM
#2779   I'll be in as well. :-) Citrati 01/22/17 12:48:26 AM
PostSubject